Eton Pharmaceuticals, Inc. (ETON) vs Kailera Therapeutics, Inc. (KLRA)
A side-by-side comparison of Eton Pharmaceuticals, Inc. and Kailera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ETON
Eton Pharmaceuticals, Inc.
$54.77HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KLRA
Kailera Therapeutics, Inc.
$10.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ETON vs KLRA
growth of $100 · dividends reinvested · last 1yETON +122.1% (+122.1%/yr)KLRA -58.3% (-58.3%/yr)ETON compounded faster over this window
Log scale — wide-divergence pair
ETON KLRA
ETON vs KLRA: by the numbers
- •ETON is the larger company ($1.50B vs $1.40B market cap).
- •ETON is profitable (12.02% net margin) while KLRA runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ETON | KLRA |
|---|---|---|
| P/E ratio | 142.41 | N/A |
| Forward P/E | 50.36 | N/A |
| P/S ratio | 14.21 | N/A |
| P/B ratio | 32.21 | 1.25 |
| EV / EBITDA | 72.05 | N/A |
| FCF yield | 0.98% | N/A |
Profitability
| Metric | ETON | KLRA |
|---|---|---|
| Gross margin | 57.87% | 0.00% |
| Operating margin | 0.09% | 0.00% |
| Net margin | 12.02% | 0.00% |
| ROE | 27.24% | N/A |
| ROIC | 20.41% | -24.52% |
Growth (annualized)
| Metric | ETON | KLRA |
|---|---|---|
| Revenue CAGR (5Y) | 47.98% | N/A |
| Total return CAGR (5Y) | 63.04% | N/A |
Frequently asked
- Is ETON or KLRA more profitable?
- ETON runs the higher net margin — ETON at 12.02% versus KLRA at 0.00%.
Go deeper
Dig into the metrics
Eton Pharmaceuticals P/E ratioEton Pharmaceuticals ROEKailera Therapeutics ROEEton Pharmaceuticals operating marginKailera Therapeutics operating marginEton Pharmaceuticals revenue growthKailera Therapeutics revenue growthEton Pharmaceuticals free cash flowKailera Therapeutics free cash flow
Eton Pharmaceuticals & Kailera Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.